Corcept Therapeutics

Corcept Therapeutics is a biopharmaceutical company specializing in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of cortisol. The company has developed over 1,000 selective proprietary cortisol modulators and received FDA approval for Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). ([corcept.com](https://corcept.com/about?utm_source=openai))